Amsterdam Molecular Therapeutics appoints chief medical officer

Dutch human gene therapy specialist hires Carlos Camozzi

Amsterdam Molecular Therapeutics (AMT), a Netherlands-based human gene therapy specialist, has appointed Carlos Camozzi as chief medical officer. He has more than 25 years of pharmaceutical industry experience, most recently within the orphan drug field. This includes overseeing product approvals at the European Medicines Agency and US Food and Drug Administration.

Camozzi joins AMT on 18 July from Orphan Europe, where he held the position of medical director for more than five years. Prior to this, he was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities.

From 2001–2005, Camozzi was md of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programmes for pharmaceutical and healthcare products.

Dr Camozzi started his career in South America holding roles at Lederle/American Cyanamid and F Hoffmann La-Roche.

You may also like

Research & Development

AMT receives €1.1m funding as part of EU consortium grant

For Acute Intermittent Porphyria (AIP) gene therapy
Manufacturing

AMT to supply manufacturing for gene therapy product

For a rare genetic disorder in children
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Subscribe now